Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%

Coria Laboratories

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Atralin (tretinoin) Gel, 0.05%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00604032

029-066-09-001

Details and patient eligibility

About

To assess the potential of tretnoin gel 0.05% to produce phototoxic reactions, measured as skin reactions 24 and 48 hours after UV radiation of drug on skin.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Normal healthy volunteers
• 18 years of age or older

Exclusion criteria

• Less than 18 years of age

Trial design

60 participants in 1 patient group, including a placebo group

1

Placebo Comparator group

Treatment:

Drug: Atralin (tretinoin) Gel, 0.05%